An innovative hair growth solution
Therapy-07
Prescription
This innovative triple combination therapy promotes hair regrowth in men with androgenic alopecia. Its exclusive combination of molecules acts at various stages of the hair growth cycle to stop hair loss and stimulate regrowth, while also making hair appear thicker. The effectiveness of this revolutionary solution was proven in the first two phases of clinical trials, where participants all observed positive results that ranged from moderate to exceptional.
PHASE III CLINICAL TRIALS 2023
Product highlights
Therapy-07
Maximum regrowth
formula for men only
Single daily
topical application
Triple combination
synergy
Product
milestones
Dr. Asotra initiates the appropriate R&D workshops and regulatory work to establish a clear roadmap for the Phase III clinical trials greenlighted by the FDA and Health Canada. To this end, he sets up several working committees to guarantee reliable active ingredient sourcing, stability testing and pharmacokinetic testing.
Identification and meeting with potential pharma partners to accelerate the commercialization of TH-07 in major markets with unmet needs.
The Triple Hair team is set to initiate Phase III clinical trials in Canada and the United States for their TH-07 triple combination therapy. The trial will involve double-blinded, randomized, placebo-controlled, parallel-group tests, take place over a year and be conducted in multiple Canadian and U.S. sites.
network
Target distribution channels
Although we ultimately want to launch our product globally, these would be our initial distribution channels for Therapy-07.
Subscribe to our waiting list
We are working hard to get the product to market as soon as possible. Sign up for the waiting list to be notified when it will be available in your country.